Because the most results of clinical trials of anti-CXCL8 or C-X-C motif chemokine receptor 2 (CXCR2) antagonists in asthma or chronic obstructive pulmonary disease (COPD) are disappointing, these bring into question the role of CXCL8-mediated neutrophil recruitment in the pathogenesis of asthma and COPD [20, 21]. Here, CXCR2 is linked to chronic obstructive pulmonary disease.